Medical Health & Life Science Research News

Gastrointestinal stromal tumor (GIST) drugs pipeline therapeutics review H1 2017 explored in latest research

Gastrointestinal stromal tumor (GIST) drugs pipeline therapeutics review H1 2017 explored in latest research

Learn details of Gastrointestinal Stromal Tumor (GIST) Pipeline therapeutics Review H1 2017. The report reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) by companies and universities/research institutes based on information derived from company and industry-specific sources. The report reviews key players involved Gastrointestinal Stromal Tumor (GIST) therapeutics and enlists all their major and minor projects

- Agency -.

Gastrointestinal Stromal Tumor (GIST) Pipeline Review H1 2017 report provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Inquire for Complete PDF Report @ www.reportsnreports.com/contacts/i…aspx?name=1057915

Additionally, the report provides an overview of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. Gastrointestinal Stromal Tumor (GIST) is cancer that starts in the endometrium, the lining of the uterus (womb).

- Agency -.

Gastrointestinal Stromal Tumor (GIST) is the most common type of uterine cancer.

Description of Report:

Gastrointestinal Stromal Tumor (GI…ne Review H1 2017 guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 16, 11, 3 and 1 respectively.

Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report features investigational drugs from across globe covering therapy areas and indications.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information.

Key Companies Analyzed In Report:

AB Science SA , Advanced Accelerator Applications SA , Advenchen Laboratories LLC , Ariad Pharmaceuticals Inc , Arog Pharmaceuticals Inc , ArQule Inc , Array BioPharma Inc , Astex Pharmaceuticals Inc , Blueprint Medicines Corp , Boston Biomedical Inc , Calithera Biosciences Inc , Celldex Therapeutics Inc , Chipscreen Biosciences Ltd , CytRx Corp , Deciphera Pharmaceuticals LLC , Exelixis Inc , F. Hoffmann-La Roche Ltd , Hanmi Pharmaceuticals Co Ltd , Horizon Pharma Plc , Immunicum AB , Jiangsu Hengrui Medicine Co Ltd , Natco Pharma Ltd , Nerviano Medical Sciences Srl , Novartis AG , Omeros Corp , Pharma Mar SA , Plexxikon Inc , Rhizen Pharmaceuticals SA , Taiho Pharmaceutical Co Ltd.

Drug Profile Discussed In Report:

aldoxorubicin hydrochloride , amcasertib, apatinib , ARQ-092 , binimetinib, BLU-285, buparlisib hydrochloride, cabozantinib s-malate, CB-839, CDX-0158, CHMFLKIT-110, crenolanib besylate, CS-2164, dabrafenib mesylate + trametinib dimethyl sulfoxide, DCC-2618, everolimus, HM-95573, interferon gamma-1b, Intuvax , masitinib, nilotinib , NMSP-088, NRCAN-019 , onalespib, Peptide to Antagonize GRPR for Oncology, pexidartinib, PLX-9486 , PM-184, ponatinib hydrochloride , SF-1126 , SHR-1020.

Get Report @ www.reportsnreports.com/contacts/d…aspx?name=1057915

The report reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) by companies and universities/research institutes based on information derived from company and industry-specific sources. The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities. The report reviews key player’s involved Gastrointestinal Stromal Tumor (GIST) therapeutics and enlists all their major and minor projects.

The report assesses Gastrointestinal Stromal Tumor (GIST) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects.

The report reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST)

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST). Identify potential new clients or partners in the target demographic.

Develop strategic initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.

Devise corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Access Report: www.reportsnreports.com/purchase.aspx?name=1057915

Major Table OF Content

  • Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017 30
  • Number of Products by Stage and Mechanism of Action, H1 2017 31
  • Number of Products by Stage and Route of Administration, H1 2017 33
  • Number of Products by Stage and Molecule Type, H1 2017 35
  • Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H1 2017 50
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by AbbVie Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ability Pharmaceuticals SL, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories LLC, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Aeterna Zentaris Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by ArQule Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by AstraZeneca Plc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Bayer AG, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by BioNTech AG, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by CBT Pharmaceuticals Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Cellceutix Corp, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Critical Outcome Technologies Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by CytomX Therapeutics Inc, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Eisai Co Ltd, H1 2017
  • Gastrointestinal Stromal Tumor (GIST) - Pipeline by Eli Lilly and Company, H1 2017

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.